

Index

- Abbott, A., 481, 491, 493
- Abnormal earnings growth (AEG) model, 172, 175–176
- Wal-Mart example, 176–180
- Accenture Ltd (ACN):
- New Constructs analytic approach, 185, 204–210
 - NOPAT, invested capital, WACC calculations, 220–224
- Accounting:
- building versus destroying value and, 28–29
 - data sources and, 62
 - differs from finance, 32
 - economic profit calculations and, 241–244
 - financial drivers and value-based finance, 154–157
 - LifeCycle system and converting information to economic returns, 274–285
 - New Constructs analytic approach, 187–188
 - value-based finance shift to economics from, 137–140
- Accounting Principles Board, 392
- Accounting Series Release (ASR) 118, of SEC, 394
- Accuracy, of automated DCF models, 116–120
- Acquisitions, life cycle of companies and, 8
- Adjusted net asset method, USPAP standards and dental practices, 456
- Adjusted present value (APV) model, 68
- Allied Capital Corporation, 387–388
- American Dental Association, 443–444
- American Institute of Certified Public Accountants (AICPA), 392, 397, 400, 402, 409
- American options, defined, 335
- American Society of Appraisers (ASA), 395, 396
- Amihud, Yakov, 483, 491
- Analysis of Equity Investments: Valuation* (Stowe), 172
- Anheuser-Busch, 525–526, 530–531
- Appraisal Foundation, 396, 397–398, 443–444
- Arbitrage. *See* Growth Rate Arbitrage Price Equilibrium System (GRAPES) theory
- Arbitrage pricing theory (APT), 25
- Arnott, R., 110
- Asset-based approach:
- dental practice valuation, 448–450
 - health care practice valuation, 426–429
 - portfolio valuation, 401
- Assets, economic output of, 276–282
- Atra, Robert J., 405–406, 511
- Automated Valuation Service (AVS), 403
- Automation, using in valuations, 400–411. *See also*
- Discounted cash flow (DCF) model, automated model development
 - data sources, 403, 406–407
 - history and lessons of, 407–409
 - LifeCycle Returns valuation system, 565–575
 - market and income approaches, 404–406
 - software for, 403, 409–411, 412
 - work plan issues, 401–403
- Autoregressive moving average-generalized autoregressive conditional heteroskedasticity (ARMA-GARCH) process, 562–563
- Avalon Bay Communities (AVB), 218–219
- New Constructs analytic approach, 185, 191–192, 197–204
- Average Price Asian Put (AAP), 498–499, 500
- Bachelier, Louis, 560
- Back, Robbie, 346
- Bailey, W., 68–69
- Bajaj, Mukesh, 479
- Baker, H. Kent, 481
- Bakshi, G., 131, 132
- Bankruptcy, GRAPES theory and, 379–380
- Barker, R., 536
- Barro, Robert J., 563
- Benchmarking:
- company versus industry fundamentals, 32–33
 - discount for lack of liquidity and marketability, 477–480
 - health care practice risk assessment, 435
 - human capital and, 512–513
- Beneish, Messod D., 483
- Bennett, Phillip, 27
- Best Buy, 15
- Beta, life cycle of companies and, 6
- Bid-ask spread, 491

- Binomial lattices, options valuation and, 341–344
 cost of commitment, 360–362
 cost of delay, 358–360
 using, 250
- Black, Fischer, S., 336
- Black-Scholes option pricing model, 336–340
 dividend yield adjustment and, 353–354
 using, 348–349
- Black-Scholes Put (BSP), 497–498
- Black's Law Dictionary*, on goodwill, 427–428
- Blockage discount, 393–394. *See also* Discount for lack of liquidity
- Boeing, 328–329
- Bollinger, John, 577
- Bond prices, 373–374
- Book value, in GRAPES equation, 377–384
- Boston Consulting Group, 293
- Bottom-up analysis. *See* Top-down/bottom-up analysis
- Boulos, F., 257
- Bounded rationality, ranges of, 568, 577–579
- Brands, as Morningstar moats, 310–311
- Brief, Richard, 278
- Brigham, E., 289
- Brouwer, Arjan, 535
- Buffett, Warren, 16, 22, 186, 196, 214, 258, 310, 318, 530
- Business environment, top-down analysis and, 3
- Business units:
 value-based finance and, 163–170
 Value Equation and visibility of contributions, 265
- Business valuation profession, 396. *See also* Professional debates and issues
- Butler, Peter, 438–439
- Buy-sell agreement method, USPAP standards and dental practices, 467–469
- Callard, Madden & Associates, 260–261, 262, 293, 300, 301, 302
- Call options. *See* Real options valuation
- Camblain, Edouard, 528
- Campbell, J. Y., 562, 563, 575
- Capital, economic profit and, 143
- Capital asset pricing model (CAPM), 23
 CFROI and, 54–56
 discount for lack of liquidity and, 485, 486
 financial theory and, 45
 market derived discount rates and, 288–292, 299–302
 New Constructs analytic approach, 187–188
 risk and return, 561
- Capital charge (CCAP), economic profit and, 143–144, 145
- Capital estimation, EVA[®] and, 244–245
- Capitalization of income method, USPAP standards and dental practices, 453–454
- Capitalization rate, dental practice valuation, 454
- Capital market theory, 376
- Carr, P., 563
- Cash economic return (CER), 278, 280
 computing of, 282–285
 firm cash flows and, 285–287
 market derived discount rates and, 290–291
 in Morningstar DCF analysis, 318
- Cash flow return on investment. *See* CFROI[™] life-cycle valuation model
- Cash profit, valuations for managers and, 263–269
- Cash tax rate, value-based finance and, 158–162
- Center for Research in Security Prices (CRSP), 23
- Certified machinery and equipment appraisers (CMEAs), 449–450
- CFROI[®] life-cycle valuation model, 43–66
 capital asset pricing model and, 54–56
 failures and successes, 60–63
 firm's competitive life cycle, 45–49
 human capital and, 510–512
 inflation adjustments and economic returns, 49–50
 insights and plausibility judgments, 56–59
 net cash receipts and discount rate calculations, 50–56
 systems mind-set, 43–45
CFROI Valuation (Madden), 24
- Chartered Financial Analysts Institute, 387
- Chen, Nai-fu, 564
- Chen, Z., 131, 132
- Chordia, Tarun, 492
- Christensen, Clayton M., 576
- Cimasi, Robert J., 455
- Class stock, GRAPES theory and, 381
- Committee of European Securities Regulators (CESR), 536–537
- Commodities, GRAPES theory and, 382
- Company-specific risk premium (CSR_P), health care practice valuation, 438–439
- Competition:
 bottom-up analysis and sustainable advantage, 6
 top-down analysis and types of, 4–5
- Competitive analysis, used by Morningstar, 306–307, 309
- Competitive Strategy: Techniques for Analyzing Industries and Competitors* (Porter), 23, 429–430
- Constant growth EVA[®] model, 228–229
- Constantinides, George M., 491
- Continuing education, dental practice valuation and, 446
- Continuing value (CV) model, 71
- Control. *See* Discount for lack of control
- Control Premium Study*, 440

Index

621

- Convergence:
 model comparisons and, 68, 89–91
 tests of, 82–86
- Cootner, Paul, 563, 567
- Copeland, T., 69, 72
- Cost advantages, as Morningstar moats, 315–317
- Cost approaches, health care practice valuation, 433–434
- Cost of capital (CCAP):
 estimates and value of manager's time, 258
 EVA[®] and, 236–240
 GRAPES theory and, 377–384
 value-based finance and, 158–162
- Cost of Capital Annual / Cost of Capital Quarterly* (Ibbotson Associates), 24–25
- Cost of equity, health care practice valuation, 437
- Courteau, L., 131, 132
- Cox, H. A., 443
- Cox, J., 341
- Creating Shareholder Value: The New Standard for Business Performance* (Rappaport), 24
- Creative destruction, 46–47
- Credit Suisse Securities, 47
- Damodaran, Aswath, 404, 528
- Data:
 bottom-up analysis and, 5
 dental practice valuation, 443–444, 457
 new valuation techniques and, 20–27
 portfolio analysis, 403, 406–407
 relevant sources for life cycle model, 62–63
 value management and, 13
- Datar, Vinay T., 491
- Debt:
 debt to net worth ratio, dental practices, 451
 EBITDA and, 529
 effect on intrinsic value, 290–291
 GRAPES theory and, 379–380
 off-balance sheet, in Morningstar analysis, 324
- Declining phase, of life cycle, 8–9
- Default risk, GRAPES theory and, 379–380
- Delisting of stock, discount for lack of liquidity and, 481–482
- Dental practices, 443–473
 fixed asset appraisal, 448–450
 normalization, 445–448
 ratio analysis, 450–451
 trend analysis, 451–452
 USPAP standards, 452–471
- Depreciation:
 dental practice valuation, 448
 EBITDA and, 530
 economic output of assets and, 276–282
 valuations for managers and, 263–269
- Desmond, Glenn, 471
- Dietrich, Mark, 455
- Direct market comparable transactions method, health care practice valuation, 434–435
- Direct market data method (DMDM), dental practice valuation and, 444, 457, 462–465
- Disclosure:
 human capital and, 520–522
 value-based, 15–17
- Discounted cash flow (DCF) model, 38
 advantages of, 108–110
 convergence, 89–91
 goodness of fit, 87–89, 91
 health care practice valuation, 432–433
 holding and liquidity periods, 485–486
 model comparisons and, 70–73, 80–82, 91
 New Constructs analytic approach, 215–219
 professional debates and issues, 592–595
 time required for, 69
 traditional valuation by manager and, 259–260
 USPAP standards and dental practices, 454–455
 value management and, 12, 14
- Discounted cash flow (DCF) model, automated
 model development, 108–134
 advantages of using, 110–111
 data and initial parameterization, 114
 dividend discount models examined, 111–114
 literature review, 130–132
 measurement principles, 114–127
 proprietary models, 127–130
- Discounted cash flow (DCF) model, used by Morningstar, 317–331
 adjustments to, 323–325
 alternatives to, 325–326
 benefits of, 305–306
 reasons for use, 317–319
 stages of model, 319–323
 standardization and, 306
 uncertainty and margin of safety, 327–331
- Discount for lack of control (DLOC):
 dental practices, 469–470
 health care practices, 425, 440
- Discount for lack of liquidity (DLOL), 474–507
 benchmarking methods, 477–480
 empirical studies, 480–482
 historical liquidity statistics, 487–489
 holding period distinguished from liquidation period, 484
 liquidity as pricing factor, 482–484
 marketability contrasted with liquidity, 475–477
 measuring asset liquidity, 492–495
 option-based models, 497–505
 price pressure and market failure, 489–491
 publically traded equivalent value, 474–475
 quantitative approaches based on CAPM and time value, 485–486
 time/volatility models applied to, 495–497

- Discount for lack of marketability (DLOM):
 dental practices, 469–470
 health care practices, 425–426, 440
 marketability contrasted with liquidity, 475–477
- Discount rates:
 health care practice valuation, 437
 life cycle and, 50–56
- Discounts and premiums, USPAP standards and dental practices, 469–470
- Dividend discount models. *See* Gordon growth model; GROW model; ROPE model
- Dividends:
 dividend payout ratio, 8
 options and, 340
 dividend valuation model, 1–3
- DLOC. *See* Discount for lack of control
- DLOL. *See* Discount for lack of liquidity
- DLOM. *See* Discount for lack of marketability
- Dodd, David, 22, 368, 575
- Dolan, Karen, 15
- Downs, T., 131
- Earnings before interest (EBI), in Morningstar DCF analysis, 320–321
- Earnings: Measurement, Disclosure, and the Impact on Equity Valuation* (Hirst and Hopkins), 172
- Earnings per share (EPS):
 financial drivers and, 154–157
 value-based finance and, 141
 value management and disclosure, 13–17
- EBITDA, 525–543
 building versus destroying value, 29
 decline in use of, 532–533
 in Europe, 525–526, 533–537
 FASB and, 527, 531, 538–540
 in financial reporting, 531–533
 impact on U.S. capital market, 537–538
 misuses of, 32, 526–527
 “Performance Reporting” projects, 538–540
 shortcomings of, 529–531
 traditional valuation by manager and, 260
 uses of, 527–529
 Value Equation and, 268–269
- Econometrics of Financial Markets* (Campbell, Lo, MacKinlay), 575
- Economic activity, top-down analysis and, 3–4
- Economic book value (EBV):
 New Constructs analytic approach and ACN, 209–210
 New Constructs analytic approach and AVB, 202
- Economic profit (EP):
 common assumptions about, 226
 Magnifier and, 148–153
 MVA and, 145–147
 New Constructs analytic approach, 188–192, 204–208, 214, 215
 value-based finance and, 141–144, 159
- Economic profit (EVA[®]) approach, 24, 226–254
 accounting adjustment to calculate, 241–244
 basics of, 227–228
 capital estimation, 244–245
 constant growth EVA[®] model, 228–229
 cost of capital effects, 239–240
 depreciation and, 277
 forecast EVA[®] valuation model, 231–234
 free cash flow link to, 246–251
 JLG Dow Fundamental example, 245–246
 pricing implications, 240–241
 reconciliation of models, 238–239
 residual income method of valuation, 172–174, 175
 T-period EVA[®] model, 235–238
 traditional valuation by manager and, 260
 variable growth EVA[®] model, 229–231
- Economic returns:
 CFROI and, 49–50
 LifeCycle system and converting accounting information to, 274–285
 LifeCycle system and converting to intrinsic values, 285–292
- Economic value added (EVA[®]). *See* Economic profit (EVA[®]) approach
- Edelman, Richard B., 481
- Efficient markets, compared with inefficient markets, 584–585
- Efficient market theory, 368, 377
- Ehrbar, Al, 173
- Elliott, W. B., 537
- Emory, John D., 475
- Emory Business Valuation, LLC, 480
- Employees. *See* Human capital, impact of
- Employee stock options (ESOs), 184–185
- EP. *See* Economic profit
- Equity risk premium (ERP), health care practice valuation, 438
- Europe, EBITDA in, 525–526, 533–537
- European options, defined, 335
- EVA[®]. *See* Economic profit (EVA[®]) approach
- Excess earnings method:
 dental practice valuation, 455–456
 health care practice valuation, 434
- Exercise of options, 352
- Expansion phase, of life cycle, 7
- Expenses, normalization of dental practice, 446–448, 453
- eXtensible Business Reporting Language (XBRL), 395, 407
- Fabozzi, Frank J., 563, 586, 590–591
- Fade patterns, 275, 286–287, 299

- Fair market value, health care practices, 421–423
- Fair value, SFAS 157 hierarchy for, 394, 402
- Fama, Eugene, 126, 561, 562, 586
- Finance theory, value management and, 31–34
- Financial Accounting Foundation (FAF), 392
- Financial Accounting Standards Board (FASB), 387, 397, 400. *See also* Statement of Financial Accounting Standard (SFAS)
- accounting pronouncements, 389, 391–395
- EBITDA and, 527, 531, 538–540
- international standards, 397
- valuation resource group, 397–398
- Financial drivers, value-based finance and, 154–157
- Financial firms, LifeCycle system and, 290, 291
- Financial Management Association Practitioner Demand Driven Academic Research Initiative (FMA PDDARI), 60, 590, 595–597
- Financial Services Authority, 389
- Financial Studies of the Small Business* (Financial Research Associates), 436
- Fixed asset appraisal, dental practice valuation, 448–450
- Fixed capital, economic profit and, 143
- FMC Corporation, 17
- FMV Opinions, Inc., 480
- Focardi, Sergio M., 586, 590–591
- “Follow the Cash” (*Forbes*), 57
- Forecast EVA[®] valuation model, 231–234
- Forward-looking statements, 9–10, 204
- Francis, J., 131, 132
- Frankel, R., 131, 132
- Frederickson, J. R., 537
- Free cash flow (FCF):
- EVA[®] link to, 246–251
- in Morningstar DCF analysis, 319, 324
- MVA and, 146
- New Constructs analytic approach, 188–193, 201–202, 208–209, 212
- French, K., 126
- Frigo, M., 256–257
- Fundamental analysis (top-down/bottom-up), 1–6, 10
- GAAP (Generally Accepted Accounting Principles):
- as imperfect measurement system, 14
- value management and disclosure, 13–17
- Garvey, Gerald T., 483
- General Motors, 17, 324–325
- Ghemawat, P., 360–361
- Goldfarb, Bob, 309
- Goodness of fit model, 67, 69, 91
- in holdout sample, 80–82
- in initial sample, 77–80
- model comparisons and, 87–89
- Goodwill:
- economic profit and, 143
- health care practice valuation, 426–429
- Goodwill Registry, 443–444, 466–467
- Gordon growth model, 70, 112–113, 289. *See also* Constant growth EVA[®] model
- measurement principles, 115–129
- tests of accuracy, 406
- Governmental Accounting standards Board (GASB), 392
- Graham, Benjamin, 22, 183, 368, 575
- GRAPES. *See* Growth Rate Arbitrage Price Equilibrium System (GRAPES) theory
- Graziano, Ron, 54
- GROW model, 112–114
- measurement principles, 115–129
- tests of accuracy, 406
- Growth:
- bottom-up analysis and, 5
- building versus destroying value, 29–30
- in Morningstar DCF analysis, 318
- value-based finance and Magnifier, 147–153
- Growth appreciation period (GAP)
- market-implied GAP, 214
- New Constructs analytic approach, 190–192, 204, 214
- Growth depreciation period (GDP), New Constructs analytic approach, 214
- Growth investors, 370
- Growth Rate Arbitrage Price Equilibrium System (GRAPES) theory, 367–385
- arbitrage in, 370–371
- data in, 378–381
- McDonald’s and Wal-Mart examples, 383–384
- model and system, 376–378
- postulates of, 371–375
- pricing of risk in, 381–382
- summarized, 375–376
- theory of prices, 367–368
- value, price and, 368–369
- Guideline publicly traded company approach, health care practice valuation, 435
- Gurel, Eitan, 483
- Hales, Stanley, 563
- Handbook of Small-Business Valuation Formulas and Rules of Thumb* (Desmond), 471
- Harms, Travis W., 485–486
- Harris, John, 449
- Harris, Lawrence, 483
- Haspeslagh, P., 257
- Haugen, Robert, 44–45

- Health care practices, 417–442. *See also* Dental practices
 adjustments for risk, 424–426
 analysis of risk, 435–439
 approaches/methods/techniques, 430–435
 classification of assets/determination of goodwill, 426–429
 competitive forces impact, 429–430
 discounts and premiums, 439–440
 pillars of valuation, 417, 441
 standard of value/premise of value, 420–424
 valuation tenets and future trends, 417–418
 value as incremental benefit, 420–421
 value pyramid, 419–420
- Heaton, John, 491
- Hedge funds, valuation standards, 388–389, 390, 398
- Hertz, Michael, 479
- Hewitt Associates, human capital impact and, 508–524
- Hewlett-Packard, 295–296
- Hirst, D. Eric, 172, 173, 537
- Holding period, DLOL and, 477–480, 484, 487–489
- HOLT Planning Associates, 24, 262, 293
- Hoogendoorn, M., 536
- Hopkins, Patrick E., 172, 173, 537
- Hospira, 16–17
- Houston, J., 289
- Hsu, J., 110
- Huang, Chi-fu, 561
- Hudson, R., 302
- Human capital, impact of, 508–524
 future results predicted, 510–513
 life cycle models and data, 62–63
 mathematical models, 522–524
 metrics and, 509
 organizational decomposition and, 513–522
- Hurdle rate, 143
- Ibbotson Associates, 24–25, 438, 454
- IBISWorld, 388
- Ijiri, Y., 278, 290
- Illiquidity. *See* Discount for lack of liquidity
- Imperfect competition, 4
- InBev S.A., 525–526, 530–531
- Incentive compensation:
 Buffett on, 258
 value management and, 13, 18–20
- Income approach:
 dental practice valuation, 445–446, 453
 health care practice valuation, 432–433
 portfolio valuation, 401, 404–406
- Incremental benefit, 420–421
- Industry economic structure:
 life cycle models and, 61
 top-down analysis and, 4–5
- Inflation adjustments, CFROI and, 49–50
- Information, option pricing and, 347
- Initial public offerings, benchmarking and DLOM, 477–480
- Institute of Business Appraisers (IBA), 443–444, 457, 467
- Insurance, dental practice valuation and, 448
- Intangible assets. *See also* Goodwill
 economic output of assets and, 277
 economic profit and, 143
 health care practice valuation, 426–429
 as Morningstar moats, 310–312
 options pricing and, 345–346
- Intel, market and model price history, 92–100
- Internal Revenue Service, Revenue Ruling 59-60, 396
 dental practice valuation, 470–471
 health care practice valuation, 428, 431–432
- Internal Revenue Service, Revenue Ruling 68-609, 455–456, 470–471
- International Accounting Standards Board (IASB), 392–393, 397
 automation and, 400–401
 EBITDA and, 531, 536, 538–540
- International Financial Reporting Standards (IFRS), 397
 EBITDA and, 525–526, 533–538, 540
- International Organization of Securities Commissions (IOSCO), 531
- International valuation standards, 397–398
- International Valuation Standards Council (IVSC), 398
- Intrinsic value:
 defined, 1
 distribution of returns and, 564
 investor relations and, 552, 554–555
 LifeCycle and converting economic returns to, 285–292
 LifeCycle and converting to investment decisions, 292–298
 professional debates and issues, 586–588
 used by Morningstar, 305, 317–331
- Invested capital:
 calculated for Accenture, 222–223
 New Constructs analytic approach, 187, 210–211
 value-based finance and, 158–162
- Invested capital intensity (ICI):
 Magnifier and, 148
 value-based finance and, 156–157
- Investment Company Act of 1940, 388, 389–390
- Investment Company Institute (ICI), 387, 394
- Investment opportunities:
 LifeCycle and converting to intrinsic value to investment decisions, 292–298
 T-period EVA[®] model and, 235–238

Index

625

- Investor relations, 544–558
 intrinsic value and, 552, 554–555
 job skills, 553–554
 one-on-one relationships, 549–551
 primary investors and, 551–552
 service function tasks, 545–546
 value fulfillment tasks, 547–549
- Investors:
 versus speculators, 183–184
 types of, 370
 typical lack of information, 182–183
- Jensen, M., 261, 270
 Jhaveri, Viral, 54
 JLG Dow Fundamental, 245–246
 John Deere, 15, 18–20
 Jonas, Caroline, 586, 590–591
- Kadlec, Gregory B., 483
 Kahl, Matthias, 486
 Kao, J., 131, 132
 Kaplan, S., 68, 109–110, 124, 126, 131, 132
 Keynes, John Maynard, 183, 184
 Khindanova, I., 563
 Kmart, life cycle performance, 47–49
 Kodak, 17
 Koller, T., 69, 72
- Lane, Bob, 18–20
 Leamer, Edward E., 63–64
 Leasehold improvements, dental practice valuation, 449
 Leasing, in Morningstar DCF analysis, 323–324
 Lee, C., 122, 131, 132
 Liebowitz, Martin, 196
 Life cycle, of business, 6–10
 LifeCycle Returns valuation system, 273–304, 555–556
 automated valuation, 565–575
 basics of, 565–566
 converting accounting information to economic returns, 274–285
 converting economic returns to intrinsic values, 285–292
 converting intrinsic values to investment decisions, 292–298
 framework synthesized, 575–577
 market derived discount rates and CAPM beta costs of capital, 299–302
 measurement principles, 128–130
 Limited control, bottom-up analysis and, 5–6
 Lintner, John, 561
 Liquidation value method, health care practice valuation, 433–434
 Liquidity. *See also* Discount for lack of liquidity
 four dimensions of, 483
 illiquidity crises and quantitative strategies, 590–592
 in Morningstar DCF analysis, 325–326
 ratio analysis in dental practices, 450
 Littman, J., 256–257
 Litzenberger, R., 561
 Liu, Jun, 486
 Lo, Andrew W., 491, 562, 563, 575
 Location, as Morningstar moat, 315–316
 Loeb, Thomas F., 475
 Longstaff, Francis A., 484, 486
 Look Back Put (LBP), 499–505
 Lucas, Deborah J., 491
 Lynch, Anthony W., 483
- Macey, Jonathan, 482
 MacKinlay, A. C., 562, 563, 575
 Madden, Bartley, 260–261, 283, 511, 555–556
 Magnifier, value-based finance and, 147–153
 Maines, L. A., 537
 Mamaysky, Harry, 491
 Management dynamics, life cycle models and, 63
 Managers, valuations for, 255–272
 current theory and reality contrasts, 256–259
 moats and economics of business, 310
 value creation, alternative measures, 259–263
 value creation, measuring of, 269–270
 Value Equation's advantages, 263–269
 Mandelbrot, B., 302, 561, 563, 586
 Mangiero, Susan, 404
 MannKind, 330
 Margin of safety, in Morningstar's DCF analysis, 327–331
 Marketability. *See* Discount for lack of marketability
 Market approach:
 health care practice valuation, 434–435
 portfolio valuation, 401, 404–406
 USPAP standards and dental practices, 457–462
 Market derived discount rate, 288–292
 CAPM beta costs of capital and, 299–302
 Market expectations:
 Morningstar's reverse engineering of, 318–319
 New Constructs analytic approach and ACN, 210
 New Constructs analytic approach and AVB, 203–204
 Market failure, DLOL and price pressure, 489–491
 Market-implied GAP (MIGAP), 214, 217
 Market-implied investment period, 235–238
 Market prices, life cycle models and, 62
 Market-price-to-book-value (M/B) ratio, 86, 91
 convergence, 89–91
 goodness of fit, 87–89, 91
 Markets, comparison of efficient and inefficient, 584–585

- Market value added (MVA), 144–147
Magnifier and, 148–153
- Markowitz, H., 301, 561
- Mark to market, versus mark to model, 589–590.
See also Automation, using in valuations;
Portfolio valuation
- Marseille, E. A., 536
- Maturity of firm, life cycle models and, 61
- McConnell, John J., 481, 483
- McCormick and Company, Inc., 330
- McCulloch, J., 302, 561–562, 563
- McDaniel, L. S., 537
- McDonald's, GRAPES theory and, 383
- Medicare/Medicaid:
dental practice valuation, 445
health care practice valuation, 422–423
- Mendelson, Haim, 483, 491
- Mendenhall, Richard R., 483
- Mercer, Christopher, 485–486
- Merck, 9–10
- Mergerstat Review*, 440
- Meulbroeck, Lisa K., 485
- Meulbroeck model, DLOL and, 485, 486
- Microsoft, 346
- Miles, Raymond C., 444, 457, 462, 464
- Miller, J. S., 537
- Miller, Merton, 23, 186, 369, 568
- Minority discount. *See* Discount for lack of control
- Misbehavior of Markets, The* (Mandelbrot), 25
- Moats, of Buffett, 214
- Moats, used by Morningstar, 307–317
finding of, 309–310
types of, 310–317
- Model users, life cycle models and, 61–62
- Modern portfolio theory (MPT), 368, 369
- Modigliani, Franco, 23, 186, 369, 568
- Monopolies, 4–5
- Monte Carlo simulations, 353–358
- Moore, P., 110
- Morningstar approach, to analysis and valuation,
305–333. *See also* Discounted cash flow (DCF)
model, used by Morningstar
economic moats and, 307–317
fair value estimates, 25
lessons of, 331–333
- Mossin, Jan, 561
- Multiples valuation approach, 69–70
contrasted to DCF, 317–318
- Murrin, J., 69, 72
- MVA. *See* Market value added
- Naik, Marayan Y., 491
- National Association of Certified Valuation
Analysts (NACVA), 396
- National Association of Corporate Directors
(NACD), 27–28
- National Equipment and Business Brokers Institute,
449
- Net cash receipts (NCRs), life cycle and, 46, 50–56
- Net operating profit (NOP), economic profit and,
142–143
- Net operating profit after tax (NOPAT), 25, 173
calculated for Accenture, 221–222
EVA[®] and, 227–228, 241–244, 246–251
New Constructs analytic approach, 187, 211–212
- Net operating profit before tax (NOBIT) margin, 204
- Net present value (NPV), economic profit and,
229–239
- Network effects, as Morningstar moats, 313–315
- Net worth, in GRAPES theory, 372
- Newberry, S., 536
- New Constructs analytic approach, 182–225
cash flow and methodology, 188–191, 192–193,
215–219
drivers of stock market valuation, 186–187
key terms defined, 210–215
most attractive stocks and methodology,
193–194, 204–210, 220–224
most dangerous stocks and methodology,
194–195, 197–204
risk/reward rating system and, 219–220
stock-picking notes, 195–197
translating accounting data into economic
statements and methodology, 187–188,
190–191
- Ng, Chiew Leng, 54
- Noda, T., 257
- Nondepreciating assets, valuations for managers
and, 263–269
- NOPAT. *See* Net operating profit after tax
- Normal distribution, doubts about, 559–560
- Normalization financial statements, dental practice
valuation, 445–448
- Normalized earnings, in health care practice, 425
- Off-balance sheet debt, in Morningstar DCF
analysis, 324
- O'Hara, Maureen, 482
- Ohlson, J. A., 174
- O'Keefe, T., 131, 132
- Oligopolies, 4
- Olsson, P., 131, 132
- Operating leases, economic profit and, 143
- Options. *See* Real options valuation
- Organizational learning, option pricing and, 347
- Orthodontic practices, 447
- Oswald, D., 131, 132
- Pacioli, Luca, 22
- Parameter bias and model improvement, of
automated DCF models, 123–127
- Pastor, L., 491

- Patents, as Morningstar moats, 311
- PDDARI. *See* Practitioner Demand Driven Academic Research Initiative
- Penman, S., 131, 174, 176, 179
- Penny stocks, 494
- Pensions, in Morningstar DCF analysis, 323
- Perold, Andre F., 45
- Perpetuity model, 70, 73, 86–87, 91
 - convergence, 89–91
 - goodness of fit, 87–89, 91
- PIMS Principles, The* (Buzzel and Gale), 23
- Pinkerton, Keith, 438–439
- Pioneering phase, of life cycle, 6–7
- Pivotal employees. *See* Human capital, impact of
- Platform investments, option pricing and, 345–347
- Pompilo, David, 482
- Porter, Michael, 23, 429–430
- Portfolio construction. *See* Security selection, with
 - lower risk and higher returns
- Portfolio valuation, 386–416
 - accounting pronouncements, 389–390
 - automation uses in, 400–411
 - background, 386–389
 - emerging best practices, 395–397
 - FASB accounting pronouncements, 391–395
 - international standards, 397–398
 - practitioner considerations, 398–400
 - SEC guidance, 390–391
 - xBRL format, 395
- Practice/commercial goodwill, health care practice valuation, 429
- Practitioner Demand Driven Academic Research Initiative (PDDARI), 60, 590, 595–597
- Pratt, Shannon P., 26, 457, 475–476, 477, 487
- Pratt's Stats, 443–444, 457, 461
- Predictive capability, of automated DCF models, 121–123
- Premise of value, health care practice valuation, 421, 423–424
- Previous subject practice transactions, health care practice valuation, 435
- Prices:
 - DLOL, pressure, and market failure, 489–491
 - DLOL and risk, 496
 - in GRAPE equation, 377–384
 - liquidity as factor, 482–484
- Price to earnings (P/E) ratio:
 - dental practice valuation, 464
 - misuse of, 32
- Price to gross revenues, dental practice valuation, 464–466
- PricewaterhouseCoopers, 528
- Principle of substitution, 420
- Private Equity Edge: How Private Equity Players and the World's Top Companies Build Value and Wealth, The* (Laffer, Hass, Pryor), 12
- Private Equity Investment Guidelines Group (PEIGG), 387
- Process-based cost advantages, as Morningstar moat, 315
- Production flexibility, option pricing and, 345–347
- Professional debates and issues, 583–600
 - assumptions and theories needing quantification, 597–599
 - discounted cash flow methodologies, 592–595
 - efficient and inefficient markets, 584–585
 - illiquidity crises and quantitative strategies, 590–592
 - intrinsic value's meaning, 586–588
 - mark to market versus mark to model, 589–590
 - Practitioner Demand Driven Academic Research Initiative, 590, 595–597
- Professional/personal goodwill, health care practice valuation, 428
- Profitability ratio, dental practices, 450–451
- Profit Impact of Market Strategy (PIMS) Program, 23
- Project abandonment, option pricing and, 348
- Publically traded equivalent value (PTEV), 474–475
- Public Company Accounting Oversight Board (PCAOB), 398
- Pulse Engineering, 358
- Purc competition, 4
- Put options. *See* Real options valuation
- Quadratic utility, mean-variance model and, 561
- Quantitative analysis:
 - bottom-up analysis and, 5
 - option pricing and, 355–358
- Quantitative Model for Discount for Marketability (QMDM), 485–486
- Quantitative Strategies for Achieving Alpha* (Tortoriello), 25, 551
- Quant models, 25
- Quest for Value, The* (Stewart), 24
- Rachev, Svetlozar, 563
- Racheva-Iotova, B., 563
- Radcliffe, Robert, 491
- Ranges of bounded rationality, 568, 577–579
- Ratio analysis, in dental practice valuation, 450–451
- Raza, Samir, 511
- Real estate industry, valuation automation history, 407–480
- Real Options Practitioner's Guide* (Copeland and Antikarov), 25
- Real options valuation, 334–366
 - advanced applications, 351–364
 - basic applications, 345–350
 - calls and puts defined, 335–336
 - option-based models and DLOL, 496

- Real options valuation (*Continued*)
 option payoffs, capturing, 352–354
 option pricing corporate equity valuation model,
 68–69
 pricing methods, 336–344
 warnings about, 364
- Refco, Inc., 27
- Regressed analyst-generated discounted cash flow,
 69
- Regulated firms, LifeCycle system and, 290, 291
- Regulatory approvals, as Morningstar moats,
 311–312
- Rejuvenation, in life cycle, 8–9
- Residual income (RI), 172–181
 abnormal earnings growth model, 172, 175–176
 defined, 174
 economic value added and, 172–174
 residual income method of valuation, 174–175
 Wal-Mart example of, 176–180
- Restricted stocks, lack of marketability and,
 477–480
- Return on capital (ROC), EVA[®] and, 226–228
- Return on equity (ROE), in GRAPES equation,
 377–384
- Return on invested capital (ROIC):
 in Morningstar DCF analysis, 307, 320–321
 New Constructs analytic approach, 188–191,
 212–213
- Return on investment (ROI):
 health care practice valuation, 437
 traditional valuation by manager and, 260–263
- Return on net assets (RONA), accounting versus
 economics and, 278–282
- Revenue growth, New Constructs analytic
 approach, 191–192, 204
- Revenue multiplier method, USPAP standards and
 dental practices, 466–467
- Richardson, G., 131, 132
- Rietz, T. A., 563
- Risk, GRAPES theory and, 379–380, 381–382
- Risk assessment, health care practices, 419–420
 analysis methods, 435–439
 valuation adjustments for, 424–426
- Risk/reward rating system, of New Constructs,
 219–220
- RMA *Annual Statement Studies* (Risk Management
 Association), 436
- Robert W. Baird & Co., Inc., 480
- Robustness, of automated DCF models, 115,
 117–120
- Roll, Richard, 301, 492
- ROPE model, 112–114
 measurement principles, 115–129
 tests of accuracy, 406
- Ross, S., 341
- Rozeff, M., 130–132
- Ruback, R., 68, 109–110, 124, 126, 131, 132
- Rubinstein, M., 341
- Salamon, Gerald, 278
- Sale of company, in Morningstar DCF analysis,
 325–326
- Sales growth. *See* Growth
- Sanger, Gary C., 481
- Sarbanes-Oxley Act of 2002, 526, 532
- SBUs. *See* Strategic business units
- Scale, as Morningstar moat, 316
- Scenario analysis, used by Morningstar, 306, 319,
 331
- Schilit, James A., 454
- Scholes, Myron, 336
- Schumpeter, Joseph, 46–47
- Schwartz, T. E., 563
- Securities and Exchange Commission (SEC),
 387–388, 393
 Accounting Series Release 118, 394
 automation and, 401–403
 EBITDA and, 531–532, 537–538
 EDGAR, 407
 hedge funds and, 388–389
 IFRS and, 525–526
 Rule 144, 478, 480
 valuation guidance, 390–391
 Security Acts of 1933 and 1934, 389
Security Analysis (Graham and Dodd), 22, 575
 Security market line (SML), 376, 377–378
 Security selection, with lower risk and higher
 returns, 559–582
 intrinsic values and, 564
 LifeCycle Returns automated valuation models,
 565–575
 LifeCycle Returns framework, 575–577
 ranges of bounded rationality, 577–579
 stable Paretian distribution and, 560–564
 Shareholder value added (SVA). *See* Managers,
 valuations for
- Sharpe, William, 23, 368, 561
- Shiller, Robert J., 577
- Shleifer, Andrei, 483
- Silber, William L., 478
- Single-period capitalization method, health care
 valuation and, 433
- Single-scale efficiency, as Morningstar moat,
 316–317
- Smith, Richard L., 479
- Smith, Vernon, 577
- Software, for business valuation, 403, 409–411,
 412
- Solomon, Ezra, 278
- Sony, 354–355
- Sougiannis, T., 124, 126, 131
- Speculators:

- contrasted to investors, 183–184
volatility and, 370
- Stabilization phase, of life cycle, 8–9
- Stable Paretian distribution, 560–564
in LifeCycle automated valuation models, 565–575
parameters of, 561–562
- Stambaugh, Robert F., 491
- Standard of value, health care practice valuation, 420–423
- Start-up businesses, Magnifier and, 152–153
- Statement of Financial Accounting Standard (SFAS) 157, 393–395, 400
automation and, 400, 401–403
three-level hierarchy for fair value, 394, 402
- Statistics of Income: Partnership Source Book and Statistics of Income: Sole Proprietor Source Book*, 436
- Stern, Joel, 173
- Stewart, G. Bennett, 173
- Stigler, George, 46
- Stochastic variables, option pricing and, 354–355
- Stockdale, John J., 485, 486, 487, 496
- Stock market, building versus destroying value, 30–31
- Stock options, in Morningstar DCF analysis, 323
- Stocks, Bonds, Bills and Inflation Yearbook* (SBB), 438
- Stowe, John D., 172
- Stoyanov, S., 562–563
- Strategic alliances, life cycle and, 8
- Strategic business units (SBUs):
value management and, 33–34
Waterfall of SBU values, 34–35
- Subrahmanyam, Avandhar, 492
- Substitution, principal of, 420
- Summa* (Pacioli), 22
- Sunderland, John, 257
- Sustainable competitive advantage, 6
- Sutton, William, 447
- Switching costs, as Morningstar moats, 312–313
- Systematic risk, life cycle and, 6
- Systems mind-set. *See* CFROI™ life-cycle valuation model
- Tabak, David, 485
- Taiwanese companies, CFROI and, 54
- Talent Guardian™, 522–524
- Talent Quotient™, 509–519
- Tangible assets, dental practice valuation, 455–456
- Taxes, cash tax rate, 158–163. *See also* EBITDA; NOPAT
- 10-K and 10-Q documents, New Constructs analysis and, 185, 186
- Thaler, Richard, 301, 579
- Thomas, Rawley, 300, 302, 405–406, 511, 555–556
- Thomson Reuters, 528
- Time series convergence. *See* Convergence
- Time Value Model, 485, 486
- Time/volatility option models, DLOL and, 495–497
- Top-down/bottom-up analysis, 1–6, 10, 44
- Tortoriello, Richard, 551
- Toshiba, 354–355
- Total shareholder return (TSR), 259
- T-period EVA® model, 235–238
- Transparency, communicating with stockholders and, 31
- Tree of Valuation Methodologies, 20–26
- Trend analysis, in dental practice valuation, 451–452
- Unbiasedness, of automated DCF models, 121
- Uncertainty, Morningstar's handling in DCF analysis, 327–331
- Uniform discount rates, 124, 126
- Uniform Standards of Professional Appraisal Practice (USPAP), 396, 402
- Uniform Standards of Professional Appraisal Practice (USPAP), dental practices and, 450, 452–471
adjusted net asset method, 456
buy-sell agreement method, 467–469
capitalization of income method, 453–454
direct market data method, 462–465
discounted future cash flow method, 454–455
discounts and premiums, 469–470
excess earnings method, 455–456
market approach, 457–462
price to earnings, 464
price to gross revenues, 464–466
revenue multiplier method, 466–467
weighting, 470–471
- Unique asset, as Morningstar moat, 316
- United Technologies Corporation, 262, 264
- Unregulated firms, LifeCycle system and, 290, 291
- Valuation Advisors, LLC, 480
- Valuation hierarchy, 164–170
- Valuation: Measuring and Managing the Value of Companies* (Copeland, Koller, Murrin), 24
- Valuation model frameworks:
life cycle, 6–10
top-down/bottom-up analysis, 1–6, 10
- Valuation models, comparisons of, 67–107. *See also* Portfolio valuation
compared models described, 69–71
convergence, models compared, 89–91
convergence tests, 82–86
expert system for valuation, 71–77
goodness of fit, initial sample, 77–80
Intel history charts, 92–100
literature review, 68–69
models compared, 86–89
tests of DCF in holdout sample, 80–82

- Valuations:
 possible techniques for, xvii–xviii
 reasons for, xvii, 583
- Value at risk (VaR), 560
- Value-based finance (VBF), 135–171
 accounting to economics transition, 137–140
 economic profit and, 141–144
 financial drivers and, 154–157
 importance of, 136–137
 Magnifier and, 147–153
 market value added and, 144–147
 project analysis focus and, 162–170
 value profit margin and, 157–162
- Value charts, 293–294
- “Value equation,” 32
- Value in exchange, health care practice, 423–424
- Value in use, health care practice, 423
- Value investors, 370
- Value Line, 23, 293
- Value management, 11–42
 company’s losing way, 17–18
 compensation and, 18–20
 discipline and better valuation frameworks,
 35–37
 disciplined versus simplistic approaches, 27–31
 disclosures and, 15–17
 finance theory and, 31–34
 new valuation techniques and databases, 20–27
 steps to building value, 37–40
 varying perspectives on, 12–14
 Waterfall of SBU values, 34–35
- Value profit margin (VPM), 157–162
- Valuing Professional Practices & Licenses*
 (Pollock), 443
- Variable growth EVA[®] model, 229–231
- Vayanos, Dimitri, 491
- Vergoossen, R. G. A., 536
- Vioxx, 324
- Vivendi Universal S.A., 527
- Volatility, options pricing and, 351–352,
 362–364
- WACC. *See* Weighted average cost of capital
- Wal-Mart:
 GRAPES theory and, 384
 life cycle performance, 57–59
 residual income and abnormal earning growth
 models, 176–180
- Wang, Jiang, 491
- Waterfall of SBU values, 34–35
- Weighted average cost of capital (WACC)
 calculated for Accenture, 223–224
 economic profit and, 229–239
 EVA[®] and, 226–228
 market derived discount rate and, 288–292
 New Constructs analytic approach, 187–188,
 213–214
 USPAP standards and dental practices, 470–471
- Whaley, Robert F., 483
- Williamette Management Associates, 480
- Williams, Neil, 529
- Working capital, economic profit and, 143
- WorldCom, 527
- Wrick, Karen Hopper, 478
- Wu, L., 563
- Xbox video game, 346
- Yaekura, T., 124, 126, 131
- Zacks Investment Research, 25
- Zavanelli, Max, 367
- Zhang, Feng, 564
- ZPR Investment Management, Inc., 367–368